SPK8011

Spark Therapeutics Inc (NASDAQ: ONCE) released phase 1/2 SPK-8011 data in hemophilia A treatment over the weekend that fell short of what investors had hoped for. The Analyst UBS' Carter Gould downgraded Spark's stock rating from Buy to Neutral with a price target slashed from $92 to...